Literature DB >> 2626517

Endogenous opioids, stress induced analgesia, and posttraumatic stress disorder.

B A van der Kolk, M S Greenberg, S P Orr, R K Pitman.   

Abstract

The hypothesis that the animal model of inescapable shock (IES) is an appropriate model for posttraumatic stress disorder (PTSD) predicts that re-exposure to a traumatic stressor will precipitate opioid-mediated stress-induced analgesia in people with PTSD. Eight Vietnam veterans with PTSD and eight matched veterans without PTSD viewed a combat videotape under naloxone and placebo conditions in a randomized double-blind crossover design. In the placebo condition, but not after naloxone, the PTSD subjects reported a 30 percent decrease in pain intensity ratings of standardized heat stimuli after the combat videotape. Point biserial correlations revealed that change in pain perception was the most highly correlated with PTSD of all variables tested, including biochemical, physiological, and self-report. These results suggest that a centrally mediated opioid response to traumatic stimuli is an important feature of PTSD. Possible implications of this finding for the psychobiology of PTSD are discussed.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2626517

Source DB:  PubMed          Journal:  Psychopharmacol Bull        ISSN: 0048-5764


  20 in total

1.  OPRM1 and diagnosis-related posttraumatic stress disorder in binge-drinking patients living with HIV.

Authors:  Nicole R Nugent; Michelle A Lally; Larry Brown; Valerie S Knopik; John E McGeary
Journal:  AIDS Behav       Date:  2012-11

Review 2.  Animal models of anxiety disorders.

Authors:  Joachim D K Uys; Dan J Stein; Willie M U Daniels; Brian H Harvey
Journal:  Curr Psychiatry Rep       Date:  2003-08       Impact factor: 5.285

3.  Prediction of numbing and effortful avoidance in female rape survivors with chronic PTSD.

Authors:  Catherine A Feuer; Pallavi Nishith; Patricia Resick
Journal:  J Trauma Stress       Date:  2005-04

Review 4.  Pharmacologic alternatives to antidepressants in posttraumatic stress disorder: a systematic review.

Authors:  William Berger; Mauro V Mendlowicz; Carla Marques-Portella; Gustavo Kinrys; Leonardo F Fontenelle; Charles R Marmar; Ivan Figueira
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2008-12-24       Impact factor: 5.067

5.  A different kind of co-morbidity: Understanding posttraumatic stress disorder and chronic pain.

Authors:  J Gayle Beck; Joshua D Clapp
Journal:  Psychol Trauma       Date:  2011-06

6.  Pain medication use among patients with posttraumatic stress disorder.

Authors:  Ann C Schwartz; Rebekah Bradley; Kristin M Penza; Melissa Sexton; Daniel Jay; Patrick J Haggard; Steven J Garlow; Kerry J Ressler
Journal:  Psychosomatics       Date:  2006 Mar-Apr       Impact factor: 2.386

7.  Effects of trauma-related cues on pain processing in posttraumatic stress disorder: an fMRI investigation.

Authors:  Marla J S Mickleborough; Judith K Daniels; Nicholas J Coupland; Raymond Kao; Peter C Williamson; Ulrich F Lanius; Kathy Hegadoren; Allan Schore; Maria Densmore; Todd Stevens; Ruth A Lanius
Journal:  J Psychiatry Neurosci       Date:  2011-01       Impact factor: 6.186

8.  Alpha(2)-noradrenergic antagonist administration into the central nucleus of the amygdala blocks stress-induced hypoalgesia in awake behaving rats.

Authors:  J P Ortiz; L N Close; M M Heinricher; N R Selden
Journal:  Neuroscience       Date:  2008-09-03       Impact factor: 3.590

9.  Anxiety- and depressive-like responses and c-fos activity in preproenkephalin knockout mice: oversensitivity hypothesis of enkephalin deficit-induced posttraumatic stress disorder.

Authors:  Jen-Chuang Kung; Tsung-Chieh Chen; Bai-Chuang Shyu; Sigmund Hsiao; Andrew Chih Wei Huang
Journal:  J Biomed Sci       Date:  2010-04-21       Impact factor: 8.410

Review 10.  Context Processing and the Neurobiology of Post-Traumatic Stress Disorder.

Authors:  Israel Liberzon; James L Abelson
Journal:  Neuron       Date:  2016-10-05       Impact factor: 17.173

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.